SCHEMBL735441

SCHEMBL735441

CSc1ccc(C)cc1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.44
TP53 P04637 2/20 0.44
MAPT P10636 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
ALOX15 P16050 1/20 0.44
ALOX12 P18054 1/20 0.44
ALDH1A1 P00352 3/20 0.44
CYP3A4 P08684 2/20 0.44
HAO1 Q9UJM8 1/20 0.44
TSHR P16473 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
HTR1A P08908 6/20 0.43
HTR3A P46098 6/20 0.43
PKM P14618 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11261432 0.83 ALOX15 (0.48) HSD17B10TP53MAPTMEN1KMT2A
SCHEMBL3376143 0.81 MAPT (0.46) HSD17B10TP53MAPTMEN1KMT2A
SCHEMBL576257 0.81 NPC1 (0.50) HSD17B10TP53MAPTMEN1KMT2A
SCHEMBL29475022 0.81 HAO1 (0.55) HSD17B10TP53MAPTMEN1KMT2A
SCHEMBL76793 0.81 HAO1 (0.55) HSD17B10TP53MAPTMEN1KMT2A
SCHEMBL29411684 0.81 NPC1 (0.50) HSD17B10TP53MAPTMEN1KMT2A
SCHEMBL12396605 0.78 HPGD (0.51) HSD17B10TP53MAPTMEN1KMT2A
SCHEMBL11482988 0.77 HAO1 (0.43) HSD17B10TP53MAPTMEN1KMT2A
SCHEMBL1145702 0.77 HAO1 (0.43) HSD17B10TP53MAPTMEN1KMT2A
SCHEMBL13906344 0.77 ALDH1A1 (0.43) HSD17B10HPGDALDH1A1CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183481-A1 A POLYPHENYLENE SULFIDE/POLYAMIDE COMPOSITION BASF SE (DE) 2023-06-15 US disclosed
US-20230144380-A1 POLYMER HAVING EXCELLENT COMPATIBILITY WITH THERMOPLASTIC RESINS TEIJIN LIMITED (JP) 2023-05-11 US disclosed
WO-2023285136-A1 THERMOPLASTIC MOLDING COMPOSITION WITH HIGH TEMPERATURE RESISTANCE COMPRISING A POLYPHENYLENE SULFIDE BASF SE (DE) 2023-01-19 WO disclosed
US-20220134323-A1 CATALYST FOR HYDROGENATION REACTION AND METHOD FOR PRODUCING SAME LG CHEM, LTD. (KR) 2022-05-05 US disclosed
EP-3903934-A1 CATALYST FOR HYDROGENATION REACTION AND METHOD FOR PRODUCING SAME LG Chem, Ltd. (KR) 2021-11-03 EP disclosed
WO-2019052935-A1 ORGANIC SEMICONDUCTING COMPOUNDS MERCK PATENT GMBH (DE) 2019-03-21 WO disclosed
WO-2019046784-A1 COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR CORVUS PHARMACEUTICALS, INC. (US) 2019-03-07 WO disclosed
US-9988521-B2 Polyphenylene sulfide resin composition, production method thereof and reflector TORAY INDUSTRIES, INC. (JP) 2018-06-05 US disclosed
US-9957377-B2 2018-05-01 US disclosed
US-9790323-B2 Polymer conductor for lithium-ion batteries THE PENN STATE RESEARCH FOUNDATION (US) 2017-10-17 US disclosed
WO-1999010357-A1 BINUCLEAR NON-HEME IRON CATALYSTS YALE UNIVERSITY (US) 1999-03-04 WO disclosed
US-5840698-A ENZYME INHIBITORS OF MERCAPTOKETONES AND MERCAPTOALCOHOLS FOR CONTROLLING DISEASES OF TISSUE BREAKDOWN, SKIN DISORDERS, ANTIINFLAMMATORY AGENTS OR ANTITUMOR AGENTS AFFYMAX TECHNOLOGIES N.V. (GB) 1998-11-24 US disclosed
US-5831004-A Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use AFFYMAX TECHNOLOGIES N.V. (GB) 1998-11-03 US disclosed
EP-0832100-A4 NOVEL INHIBITORS OF METALLOPROTEASES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND METHODS OF THEIR USE AFFYMAX TECH NV (AN) 1998-09-02 EP disclosed
EP-0832100-A1 NOVEL INHIBITORS OF METALLOPROTEASES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND METHODS OF THEIR USE AFFYMAX TECHNOLOGIES N.V. (AN) 1998-04-01 EP disclosed
WO-1996040204-A1 NOVEL INHIBITORS OF COLLAGENASE-1 AND STROMELYSIN-I METALLOPROTEASES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND METHODS OF THEIR USE AFFYMAX TECHNOLOGIES, N.V. (AN) 1996-12-19 WO disclosed
WO-1996040738-A1 NOVEL INHIBITORS OF METALLOPROTEASES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AND METHODS OF THEIR USE AFFYMAX TECHNOLOGIES, N.V. (AN) 1996-12-19 WO disclosed
US-4289695-A REACTION OF A PHENICILLIN WITH AN N-CHLORO HALOGENATING AGENT IN PRESENCE OF A CROSSLINKED POLYVINYLPYRIDINE ELI LILLY AND COMPANY (US) 1981-09-15 US disclosed
EP-0011370-A1 Process for preparing 2-chlorosulfinyl-azetidinones ELI LILLY AND COMPANY (US) 1980-05-28 EP disclosed
US-4159272-A Process for 2-chlorosulfinylazetidin-4-ones ELI LILLY AND COMPANY (US) 1979-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220134323-A1 CATALYST FOR HYDROGENATION REACTION AND METHOD FOR PRODUCING SAME GRHPR, HAO2, RAD51 HSD17B10 230/4885TP53 3704/4885MAPT 3348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.